表紙
市場調查報告書

超高分子量聚乙烯的全球市場

Ultra-High Molecular Weight Polyethylene

出版商 Global Industry Analysts, Inc. 商品編碼 941320
出版日期 內容資訊 英文 424 Pages
商品交期: 最快1-2個工作天內
價格
超高分子量聚乙烯的全球市場 Ultra-High Molecular Weight Polyethylene
出版日期: 2020年08月01日內容資訊: 英文 424 Pages
簡介

COVID-19危機中,2020年估算為17億美元的超高分子量聚乙烯的全球市場,預測在2020年∼2027年間將以8.5%的年複合成長率成長,2027年達到31億美元。市場區隔之一的薄板部門在分析期間結束前預測將以9.2%的年複合成長率增長,達到21億美元的規模。

本報告提供超高分子量聚乙烯的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,市場規模的變化與預測,各種區分·地區·各主要國家的詳細分析,競爭環境,主要企業簡介等資料。

調查對象企業範例

  • Asahi Kasei Corporation
  • Braskem SA
  • Celanese Corporation
  • CP Medical Corp.
  • Crown Plastics, Inc.
  • DowDuPont, Inc.
  • Emco Industrial Plastics, Inc.
  • Garland Manufacturing Company
  • Global Polymers
  • Honeywell International, Inc.
  • King Plastic Corporation
  • Koninklijke DSM NV
  • Korea Petrochemical Ind. Co., Ltd.
  • LyondellBasell Industries NV
  • Mitsui Chemicals, Inc.
  • Nitto Denko Corporation
  • Orthoplastics Ltd.
  • Quadrant AG
  • Redwood Plastics
  • Rochling Engineering Plastics Pvt., Ltd.
  • SABIC (Saudi Basic Industries Corporation)
  • Shandong Ningjin Xinxing Chemical Co., Ltd.
  • Shanghai Lianle Chemical Industry Science and Technology Co., Ltd.
  • Teijin Ltd.
  • Toyobo Co., Ltd.

目錄

  • i. 簡介,調查手法 、 調查範圍

II. 摘要整理

第1章 市場概要

  • 全球其他競爭公司的市場佔有率
  • 全球超高分子量聚乙烯的競爭市場佔有率方案(%):2019年及2025年
  • Covid-19的影響和即將到來的全球景氣衰退

第2章 主要企業

第3章 市場趨勢與推動因素

第4章 全球市場預測

III. 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:41

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP15352

Manufacturing Slump Impacts demand for High Strength Engineering Plastics. UHMWPE Revenues Dip by -6.3%

The global market for Ultra-High Molecular Weight Polyethylene (UHMWPE) is expected to decline by -6.3% in response to the slumping manufacturing activity and thereafter recover and reach US$1.9 billion by the year 2027, trailing a post COVID-19 CAGR of 7.3% over the analysis period 2020 through 2027. UHMWPE is widely used as a replacement for lower grade plastics in applications requiring greater mechanical strength & stability. UHMWPE features enhanced abrasion and chemical resistance; better impact strength; improved self-lubrication & improved process ability; low friction coefficient & superior heat & water resistance. Due to the COVID-19 pandemic, governments across the globe have ordered stay-at-home orders for people and shut-down businesses engaged in the production of non-essential goods. Social distancing is considered to be a potent measure for keeping a check on spread of this pandemic. The economic impact of such restrictions on business activities is expected to be huge. Due to the outbreak, the sentiment across the industrial manufacturing sector has declined drastically during the past few months and indicates strong decline for the entire year. Although restrictions have been eased significantly in some countries, concerns over future financial insecurity is limiting the consumer purchases only to the essential items such as groceries and other basic necessities. Buying non-essential products such as electronics and automobiles is not a priority for most of the consumers now. Delays and disruptions in production, exports and imports also wield a considerable impact on the demand and hence manufacturing activity. The decline in transportation sector and parallel drop in production of automotive vehicles, aircraft, and marine vessels is curtailing the momentum in the UHMWPE market. Similarly, ban on air travel, the primary mode of global transmission of COVID-19 disease, in several parts of the world has substantially diminished the aircraft demand with several aviation companies reducing the order size or cancelling the orders altogether. Likewise, construction & mining sectors also witnessed drastic decline, while eroding demand for equipment utilized in these sectors. Against this backdrop, it is expected that UHMWPE market will register a negative growth in 2020, before making a recovery in 2021 on the premise that sentiment in end-user verticals will revive in post COVID-19 period.

Ultra-high molecular weight polyethylene (UHMWPE) is a class of thermoplastic polyethylene that presents a blend of extraordinary properties for industrial applications. Also popular as high-modulus polyethylene, the material exhibits superior resistance to corrosion and wear, displays low water absorption as well as is self-lubricating and non-sticking. The thermoplastic holds a molecular mass of 3.5-7.5 million amu and features very long polyethylene chains aligning in same direction. The overlapping of molecules or chains strengthens intermolecular interactions and allows the material to carry large loads. The unique structure results in a tough thermoplastic boasting the highest impact strength in its class. The non-toxic, tasteless and odorless material features all properties of high-density polyethylene along with superior resistance to concentrated alkalis and acids and various organic solvents. Several forms of UHMWPE exhibit 15-fold higher abrasion-resistance in comparison to carbon steel. The material's coefficient of friction is considerably lower as compared to acetal and nylon, and comparable to Teflon.

In the post COVID-19 period, strong growth in expected to come from healthcare applications. In contrast to nylon fibers, steel, and polyester materials, ultra-high molecular weight polyethylene (UHMWPE) fiber offer relatively more robust, safe, and chemical resistant solutions for end users. Given its superior features, the novel material significantly minimizes risks pertaining to infection and pain among patients. As a result, UHMWPE is widely employed nowadays in suture applications for repairing broken bones. The advanced fiber is utilized as an actuator in surgical robots for safely carrying out minimally invasive surgical procedures. Due to its compact, flexible, and lightweight features, UHMWPE allow manufacturers to design various implantable cardiovascular equipment such as covered stents and stent grafts. Innovation holds critical importance in today's highly competitive global business scenario and medical devices industry is no exception to this. Ongoing technological advancements are enabling companies to design abrasion resistant, smooth, and easy to use minimally invasive surgical devices. UHMWPE fibers comply with international standards for mutagencity, pyrogenicity, hem compatibility, sensitization/irritation, cytotoxicity, and genotoxicity. Driven by increasing popularity of minimally invasive surgeries and implants, demand for UHMWPE fibers will witness significant increase.

Competitors identified in this market include, among others,

  • Asahi Kasei Corporation
  • Braskem SA
  • Celanese Corporation
  • CP Medical Corp.
  • Crown Plastics, Inc.
  • DowDuPont, Inc.
  • Emco Industrial Plastics, Inc.
  • Garland Manufacturing Company
  • Global Polymers
  • Honeywell International, Inc.
  • King Plastic Corporation
  • Koninklijke DSM NV
  • Korea Petrochemical Ind. Co., Ltd.
  • LyondellBasell Industries NV
  • Mitsui Chemicals, Inc.
  • Nitto Denko Corporation
  • Orthoplastics Ltd.
  • Quadrant AG
  • Redwood Plastics
  • Rochling Engineering Plastics Pvt., Ltd.
  • SABIC (Saudi Basic Industries Corporation)
  • Shandong Ningjin Xinxing Chemical Co., Ltd.
  • Shanghai Lianle Chemical Industry Science and Technology Co., Ltd.
  • Teijin Ltd.
  • Toyobo Co., Ltd.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXE7CUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Pharmaceutical Contract Manufacturing - A Prelude
    • Impact of Covid-19 and a Looming Global Recession
    • COVID-19 Breaks All Things Normal, Pushes Pharmaceutical Industry into an Era of Change
    • COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply Shortages
    • US Federal Government & FDA Take Unprecedented, Bold Steps to Deal with Shortage of Pharmaceuticals
    • What Does this Spell for Pharmaceutical Outsourcing & Contract Manufacturing?
    • Market Outlook
    • The US and Europe Constitute the Largest Markets for PCM
    • Asia-Pacific to Drive the PCM Market Growth
    • Competition
    • M&A Activity High in the Contract Manufacturing Space
  • 2. FOCUS ON SELECT PLAYERS
    • Recent Market Activity
  • 3. MARKET TRENDS & DRIVERS
    • Strong Rise in Pharmaceutical Sales to Drive Demand for Pharmaceutical Contract Manufacturing
    • EXHIBIT 1: Global Prescription Drug Sales (In US$ Billion) for the Years 2017, 2019, 2021, 2023 & 2025
    • Emergence of Outsourcing Trend Bodes Well for CDMOs
    • Pharmaceutical Contract Manufacturers Adopt Advanced Manufacturing Technologies
    • Embracing Emerging Technologies
    • Exploring & Exploiting New Technologies for Rich Dividends
    • Rapid Growth of Generic Drugs Drives Demand for Pharma Contract Manufacturing
    • EXHIBIT 2: Leading Drugs Facing Patent Expiry in the US in 2020
    • EXHIBIT 3: Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025
    • Increasing Significance of Biologic Drugs Supports Market Demand
    • EXHIBIT 4: Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025
    • Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
    • EXHIBIT 5: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • EXHIBIT 6: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 7: World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Persistent Increase in Pharmaceutical R&D Bodes Well for PCM
    • EXHIBIT 8: Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
    • Increasing Sales of OTC Drugs Presents an Opportunity for Pharma Contract Manufacturing Market
    • EXHIBIT 9: Global OTC Drugs Market Breakdown by Product (in %): 2020E
    • Increasing Outsourcing of Clinical Trials to Emerging Markets
    • New Technology Promises to Improve Sterile Manufacturing Process
    • Serialization Drives New Design Developments in Pharma Sector
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 2: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 3: World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 5: World Historic Review for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 6: World 15-Year Perspective for API/Bulk Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 8: World Historic Review for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 9: World 15-Year Perspective for Advanced Drug Delivery Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 11: World Historic Review for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 12: World 15-Year Perspective for Packaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 14: World Historic Review for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 15: World 15-Year Perspective for Finished Dose Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 17: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 18: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 20: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 21: World 15-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 23: World Historic Review for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 24: World 15-Year Perspective for Biopharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 26: World Historic Review for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 27: World 15-Year Perspective for Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 29: World Historic Review for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 30: World 15-Year Perspective for Non-Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • TABLE 31: USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 32: USA Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 33: USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 34: USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 35: USA Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 36: USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 38: USA Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 39: USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 40: Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 41: Canada Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 42: Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 44: Canada Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 45: Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 46: Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 47: Canada Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 48: Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 49: Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 50: Japan Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 51: Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 52: Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 53: Japan Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 54: Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 55: Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 56: Japan Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 57: Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 58: China Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 59: China Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 60: China 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 61: China Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 62: China Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 63: China 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 64: China Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 65: China Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 66: China 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 67: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 68: Europe Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 69: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 71: Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 72: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 74: Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 75: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 76: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 77: Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 78: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 79: France Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 80: France Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 81: France 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 82: France Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 83: France Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 84: France 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 85: France Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 86: France Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 87: France 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 88: Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 89: Germany Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 90: Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 91: Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 92: Germany Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 93: Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 94: Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 95: Germany Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 96: Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 97: Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 98: Italy Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 99: Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 100: Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 101: Italy Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 102: Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 103: Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 104: Italy Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 105: Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 106: UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 107: UK Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 108: UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 109: UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 110: UK Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 111: UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 112: UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 113: UK Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 114: UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 115: Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 116: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 117: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 118: Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 119: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 120: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 121: Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 122: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 123: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 124: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 125: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 126: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for India and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 127: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 128: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 129: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 130: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 131: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 132: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 133: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 134: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 135: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 136: India Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 137: India Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 138: India 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 139: India Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 140: India Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 141: India 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 142: India Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 143: India Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 144: India 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 145: Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 146: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 147: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 148: Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 149: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 150: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 151: Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 152: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 153: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 154: Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 155: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 156: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 157: Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 158: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 159: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 160: Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 161: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 162: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 192